title: Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies.
abstract: A discussion of rational endpoints in clinical trials seeking regulatory approval for new anti-neoplastic agents involving the three major gynecologic malignancies, cancers of the ovary, cervix, and endometrial, is particularly interesting as (in the opinion of this commentator) the conclusion will be different in the individual cancers.
authors.affiliation: Cancer Treatment Centers of America, Philadelphia, PA, USA Drexel University College of Medicine, Philadelphia, PA, USA maurie.markman@ctca-hope.com.
authors.forename: Maurie
authors.initials: M
authors.lastname: Markman
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017277:Drug Approval; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000970:Antineoplastic Agents
keywords: cervical cancer; chemotherapy of gynecologic cancers; cisplatin; endometrial cancer; gynecologic cancers; ovarian cancer; randomized trials